Literature DB >> 17210890

Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.

M A Kroos1, R J Pomponio, M L Hagemans, J L M Keulemans, M Phipps, M DeRiso, R E Palmer, M G E M Ausems, N A M E Van der Beek, O P Van Diggelen, D J J Halley, A T Van der Ploeg, A J J Reuser.   

Abstract

BACKGROUND: Pompe disease (acid maltase deficiency, glycogen storage disease type II; OMIM 232300) is an autosomal recessive lysosomal storage disorder characterized by acid alpha-glucosidase deficiency due to mutations in the GAA gene. Progressive skeletal muscle weakness affects motor and respiratory functions and is typical for all forms of Pompe disease. Cardiac hypertrophy is an additional fatal symptom in the classic infantile subtype. c.-32-13T-->G is the most common mutation in adults.
OBJECTIVE: To delineate the disease variation among patients with this mutation and to define the c.-32-13T-->G haplotypes in search for genotype-phenotype correlations.
METHODS: We studied 98 compound heterozygotes with a fully deleterious mutation (11 novel mutations are described) and the common c.-32-13T-->G mutation.
RESULTS: All patients were Caucasian. None had the classic infantile form of Pompe disease. The clinical course varied far more than anticipated (age at diagnosis <1 to 78 years; age at onset: <1 to 52 years). The acid alpha-glucosidase activities in a subset of patients ranged from 4 to 19.9 nmol/mg/h. Twelve different c.-32-13T-->G haplotypes were identified based on 17 single-nucleotide polymorphisms located in the GAA gene. In 76% of the cases, c.-32-13T-->G was encountered in the second most common GAA core haplotype (DHRGEVVT). In only one case was c.-32-13T-->G encountered in the major GAA core haplotype (DRHGEIVT).
CONCLUSION: Patients with the same c.-32-13T-->G haplotype (c.q. GAA genotype) may manifest first symptoms at different ages, indicating that secondary factors may substantially influence the clinical course of patients with this mutation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210890     DOI: 10.1212/01.wnl.0000252798.25690.76

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

2.  Molecular diagnosis of German patients with late-onset glycogen storage disease type II.

Authors:  P R Joshi; D Gläser; S Schmidt; M Vorgerd; M Winterholler; K Eger; S Zierz; M Deschauer
Journal:  J Inherit Metab Dis       Date:  2008-07-10       Impact factor: 4.982

3.  Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.

Authors:  Sueli M Oba-Shinjo; Roseli da Silva; Fernanda G Andrade; Rachel E Palmer; Robert J Pomponio; Kristina M Ciociola; Mary S Carvalho; Paulo S Gutierrez; Gilda Porta; Carlo D Marrone; Verônica Munoz; Anderson K Grzesiuk; Juan C Llerena; Célia R Berditchevsky; Claudia Sobreira; Dafne Horovitz; Thamine P Hatem; Elizabeth R C Frota; Rogerio Pecchini; João Aris Kouyoumdjian; Lineu Werneck; Veronica M Amado; José S Camelo; Robert J Mattaliano; Suely K N Marie
Journal:  J Neurol       Date:  2009-07-09       Impact factor: 4.849

4.  Identification and Functional Characterization of GAA Mutations in Colombian Patients Affected by Pompe Disease.

Authors:  Mónica Yasmín Niño; Heidi Eliana Mateus; Dora Janeth Fonseca; Marian A Kroos; Sandra Yaneth Ospina; Juan Fernando Mejía; Jesús Alfredo Uribe; Arnold J J Reuser; Paul Laissue
Journal:  JIMD Rep       Date:  2012-04-19

Review 5.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

Review 6.  Diagnostic tools in late onset Pompe disease (LOPD).

Authors:  Olimpia Musumeci; Antonio Toscano
Journal:  Ann Transl Med       Date:  2019-07

7.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

8.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Authors:  Mugdha V Rairikar; Laura E Case; Lauren A Bailey; Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-09-19       Impact factor: 4.797

9.  Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Authors:  Claudio Semplicini; Pascaline Letard; Marie De Antonio; Nadjib Taouagh; Barbara Perniconi; Françoise Bouhour; Andoni Echaniz-Laguna; David Orlikowski; Sabrina Sacconi; Emmanuelle Salort-Campana; Guilhem Solé; Fabien Zagnoli; Dalil Hamroun; Roseline Froissart; Catherine Caillaud; Pascal Laforêt
Journal:  J Inherit Metab Dis       Date:  2018-08-28       Impact factor: 4.982

10.  Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.

Authors:  Yunxiang Zhu; Ji-Lei Jiang; Nathan K Gumlaw; Jinhua Zhang; Scott D Bercury; Robin J Ziegler; Karen Lee; Mariko Kudo; William M Canfield; Timothy Edmunds; Canwen Jiang; Robert J Mattaliano; Seng H Cheng
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.